Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
By using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 in a iontophoretic device for the treatment of Parkinson's disease, it became possible to obtain a rotigotine flux across the human stratum corneum which was higher than the one previously obtained with conventional passive diffusion systems.
1. A method for treatment of Parkinson's disease comprising applying an iontophoretic device, which comprises a composition comprising (a) rotigotine in a concentration sufficient to provide a therapeutically effective rotigotine flux for treatment of Parkinson's disease, and (b) at least one chloride salt selected from the group consisting of triethylammonium chloride, tributylammonium chloride and combinations thereof in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5, onto skin of a patient in need thereof.
2. The method of claim 1 , wherein the concentration of rotigotine in the composition is at least 0.5 mg/ml.
3. The method of claim 1 , wherein the concentration of rotigotine in the composition is 0.5 to 3 mg/ml.
4. The method of claim 1 , wherein the concentration of the chloride salt is 60 to 80 mmol/l.
5. The method of claim 1 , wherein the composition forms a donor phase of the iontophoretic device.
6. The method of claim 5 , wherein the composition forming the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylanimonium chloride and tributylanimonium chloride in a concentration of 60 to 80 mmol/l, and wherein the pH of the donor phase is 4.5 to 5.5.
7. A method for treatment of Parkinson's disease comprising applying an iontophoretic device, which comprises a composition comprising (a) rotigotine in a concentration sufficient to provide a therapeutically effective rotigotine flux for treatment of Parkinson's disease, and (b) at least one pharmaceutically accentable chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5, onto skin of a patient in need thereof.
8. The method of claim 7 , wherein the concentration of rotigotine in the composition is at least 0.5 mg/ml.
9. The method of claim 7 , wherein the concentration of rotigotine in the composition is 0.5 to 3 mg/ml.
10. The method of claim 7 , wherein the at least one chloride salt is selected from NaCl, triethylanimonium chloride and tributylammonium chloride.
11. The method of claim 7 , wherein the concentration of the chloride salt is 60 to 80 mmol/l.
12. The method of claim 7 , wherein the composition forms a donor phase of the iontophoretic device.